Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
menotropin + GnRH antagonist
- Development stage
- Unknown
- Lead developer
- Ferring Pharmaceuticals
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Administration
- Subcutaneous, Intramuscular
01
Overview
hMG + GnRH antagonist is a combination drug intervention used for controlled ovarian stimulation in women undergoing assisted reproductive techniques, such as intrauterine insemination (IUI). The combination consists of highly purified human menotropin (hMG-HP), marketed by Ferring Pharmaceuticals as Menopur, and a gonadotropin-releasing hormone (GnRH) antagonist. Menotropin provides both follicle-stimulating hormone (FSH) and luteinizing hormone (LH) activity to stimulate the growth and maturation of multiple ovarian follicles. The GnRH antagonist component acts by competitively binding to GnRH receptors in the pituitary gland, which rapidly suppresses the secretion of endogenous gonadotropins and prevents premature LH surges that could otherwise trigger untimely ovulation. This protocol is designed to improve clinical pregnancy rates by optimizing the timing of ovulation induction.
- Brand names
- Menopur
- Other names
- hMG + GnRH antagonisthuman menopausal gonadotropin + gonadotropin-releasing hormone antagonistmenotropin + GnRH antagonist
02
Targets
FSHR (Follicle-stimulating hormone receptor)LHCGR (Luteinizing hormone/choriogonadotropin receptor)GnRHR (Gonadotropin-releasing hormone receptor)
Beyond the preview
Go deeper on menotropin + GnRH antagonist.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on menotropin + GnRH antagonist.